MOVE FORWARD WITH HIZENTRA
Initiating Therapy
Initiate therapy 1 week after last IVIg infusion
Hizentra takes approximately 1 hour to self-infuse per week*
When transitioning from IVIg to Hizentra 1 week after the last IVIg infusion, immunomodulation is continued without disruption.1
To avoid potential delays, enroll your eligible patients in the Free Trial Program.
*Infusion time may be shorter or longer depending on the dose, flow rate, and number of infusion sites used.
The recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week, administered in 1 or 2 sessions over 1 or 2 consecutive days.
View additional infusion parameters.
Hizentra has broad national coverage
- The Hizentra Copay Program provides eligible patients with commercial insurance up to $20,000 in copay assistance per calendar year
†As of July 2025. Prior authorization or step therapy may be required.
‡Subject to terms and conditions of the Copay Support Program, available here.
Enrollment
Start your patients on Hizentra today
To prevent any potential delays in starting Hizentra, submit both the Prescription Referral and Free Trial Enrollment forms to Hizentra Connect.
Leverage the Prior Authorization Checklist, and verify you have the patient and diagnostic information that insurers often require. Reference the Billing and Coding Guide for support.
Patient Support Program
Hizentra Connect is a suite of support programs and resources to optimize your patient’s experience and provide ongoing support through their journey.
To get the guidance and support you need:
Call 1-877-355-4447 Monday-Friday, 8 AM to 8 PM ET.
Abbreviation: IVIg, intravenous immunoglobulin.
References: 1. Tortorici MA, Yuraszeck T, Cornblath D, et al. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):839-850. doi:10.1002/psp4.12647 2. Data on File. Available from CSL Behring as DOF HIZ-019. 3. GBS|CIDP Foundation International. Published July 16, 2021. Accessed September 10, 2026. https://www.gbs-cidp.org/2021/07/medicare-b-will-cover-an-immunoglobulin-therapy-for-patients-with-cidp-starting-july-18-2021/
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.